Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
A new treatment targeting two tumor-feeding genes is being tested to treat non-small cell lung cancer. The therapy, called PEPD-G278D, breaks down genetic mutations that contribute to drug resistance, showing strong suppression of NSCLC cell function and tumors.
A new editorial published in Aging suggests that starting targeted cancer therapies with high concentrations may slow down the selection for resistance. This approach could potentially be used as a preemptive measure to minimize the development of resistance.
A recent study published in CANCER found that patients with metastatic non–small cell lung cancer treated with immunotherapy had improved overall and cancer-specific survival rates compared to those without it. The median overall survival was eight months, while cancer-specific survival was 10 months.
Recent studies from Asia indicate that low-radiation dose computed tomography screening is more effective in detecting cancers in those with a family history of lung cancer, but the benefits are uncertain for never-smokers. The authors advocate for more rigorous research to understand the benefits and harms of screening this population.
A study by McGill University researchers has found a link between ultrafine particle exposure and increased mortality risk, particularly for respiratory deaths and coronary artery disease. Long-term exposure to these tiny particles is associated with a 7.3% increase in non-accidental death risk.
A new study published by Ohio State University has found that vaping combined with cigarette smoking increases the risk of lung cancer four times higher than people who only smoke. Researchers analyzed data from over 4,975 patients with lung cancer and a control group of 27,294 people without cancer.
A recent study published in Frontiers in Immunology highlights the crucial role of tissue-resident memory T cells in non-small cell lung cancer. The research found that these cells can significantly impact patient outcomes and guide personalized treatment strategies, particularly those involving immunotherapy.
The review highlights the controversy surrounding asbestos-related research and the varying results on its carcinogenicity. It emphasizes the need for high-quality, independent studies to resolve existing debates and inform public health policies.
The American College of Chest Physicians has released a new clinical guideline for managing central airway obstruction, providing evidence-based recommendations to guide its management. The guideline emphasizes the importance of shared decision-making and a multidisciplinary approach in optimizing care and improving outcomes.
Scientists have successfully collected and profiled lung biomarkers from human breath, developing animal models to identify key markers for early detection of metastatic lung tumors. The research establishes a scientific roadmap for an exhaled-breath test, which may revolutionize the diagnosis and surveillance of human lung diseases.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
Researchers developed an AI model that can estimate lung function from chest radiographs with high accuracy, potentially expanding options for pulmonary function assessment in patients who have difficulty performing spirometry. The study found a remarkably high agreement rate between the AI model's estimates and actual spirometric data.
The study identified RNF144B as a tumour suppressor that prevents genomic instability, but low expression leads to poor prognosis and treatment resistance in lung adenocarcinoma. The research suggests that even non-mutated genes like RNF144B can have a significant impact on cancer development.
Scientists have mapped over 5,000 genetic variants in the 'tumour protection' gene BAP1 that significantly increase cancer risk. These variants can be used to develop new treatments, including IGF-1 inhibitors, to slow down or prevent cancer progression.
A cross-sectional study found that e-cigarette users were less likely to undergo lung cancer screening. The research suggests that e-cigarettes contain carcinogens and may cause similar gene deregulations as combustible tobacco. This association may be particularly concerning for individuals who have quit smoking combustible cigarettes.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
Researchers found that stress responses differ between patients living in high-violence areas and those in lower-crime zones. The study suggests glucocorticoid receptors play a key role in driving adverse tumor outcomes in patients with chronically high environmental stress.
Researchers found that adding an anti-inflammatory drug to immune checkpoint inhibitor therapy resulted in a high response rate of 67% among patients with stage 4 non-small cell lung cancer. The study suggests that reducing chronic inflammation may improve the effectiveness of immunotherapy.
Researchers analyzed three tumor markers for associations with radiographic response and clinical outcomes in NSCLC patients. The study found that CEA, CA-125, and CA-19-9 were associated with progression and radiographic responses in NSCLC.
Researchers at Weill Cornell Medicine developed an artificial intelligence-powered method for detecting tumor DNA in blood, showing high sensitivity and accuracy in predicting cancer recurrence. The technology, called MRD-EDGE, can detect subtle patterns in sequencing data to distinguish between cancer and non-cancerous signals.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
Researchers discovered that lung cancer cells with specific genetic mutations, including EGFR and p53, are more likely to double their genome, leading to drug resistance. This discovery has implications for the development of targeted treatments for non-smoking lung cancer patients.
Researchers developed microscopic robots that swim through lungs to deliver cancer-fighting medication directly to metastatic tumors. The approach inhibited tumor growth and spread, improving survival rates compared to control treatments.
US Veterans Health Administration data shows lung cancer screening before diagnosis increases early stage detection and lower mortality rates. Researchers found that those who underwent screening had a higher cure rate and improved survival over five years compared to those without screening.
Generation X sees gains in leading cancers, but lower rates of lung and cervical cancers compared to previous generations. Cancer incidence could remain high for decades if current trends continue.
Researchers found that only 41.5% of cancer patients could successfully book a new appointment at a clinic due to various barriers, including language issues and workflow challenges.
Researchers developed an AI-driven liquid biopsy to identify lung cancer through DNA fragment patterns in the blood, demonstrating a high negative predictive value of 99.8%. The test could quadruple lung cancer detection rates and prevent thousands of deaths if implemented nationwide.
A new study has found a strong association between sleep apnea-induced hypoxemia and the risk of lung cancer reoccurrence. The research involved a retrospective record review of adult patients with non-small cell lung cancer, finding that measures of hypoxic burden were strongly correlated with accelerated cancer reoccurrence.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
A stepped-care model integrating palliative care at key points in patients' cancer trajectories shows reduced palliative care visits without compromising quality of life. The approach enables more efficient delivery of early palliative care, enhancing patient-reported outcomes.
A randomized trial found that stepped palliative care, which adjusts the intensity of care based on patient-reported quality of life, is a non-inferior alternative to traditional early palliative care. The study included 507 patients with advanced lung cancer and showed improved patient outcomes without increasing healthcare costs.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
A study by Sylvester Comprehensive Cancer Center found that durvalumab, a targeted immunotherapy for lung cancer, exceeded official cost-effectiveness thresholds in four countries: the US, Brazil, Singapore, and Spain. The drug's high cost-effectiveness ratio was due to its extended lifespan and quality-of-life benefits.
Researchers from Mass General Cancer Center are set to present key findings on palliative care delivery via telehealth versus in-person for patients with advanced lung cancer. The presentations also cover advances in colorectal and breast cancer treatments, as well as results from a phase 1b/2 study on a novel BRAF inhibitor.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
A study analyzing data from the National Cancer Database found that patients receiving care at minority-serving hospitals were 17% less likely to receive definitive treatment for breast cancer and up to 31% less likely for prostate, lung, and colon cancers. Improving treatment rates could lead to additional patient outcomes.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
A recent study uses AI to analyze body composition in patients with lung cancer treated with immunotherapy, finding that changes in muscle mass and fat quality are important indicators of outcomes. The research provides a more nuanced understanding of the relationship between body composition and response to immunotherapy.
A novel gene cluster expression analysis was introduced to potentially expand treatments for more lung cancer patients. The study found that a gene cluster expression index can classify cancers with dramatically different recurrence risks, with higher risk groups suitable for targeted therapy or immunotherapy.
Researchers from Mount Sinai will present new research on long COVID, lung cancer, asthma, and sleep apnea at the ATS 2024 International Conference. The studies aim to improve diagnosis and care for these conditions.
A new study by University of Liverpool researchers demonstrates that lung cancer screening offers comparable benefits to all socioeconomic groups, reducing deaths from COPD and emphysema. The study highlights the importance of targeted screening programs for disadvantaged populations.
A nationwide cohort study found that ex-smokers who vape after quitting cigarettes are at a higher risk of developing lung cancer and dying from it. The study analyzed over 4 million individuals and categorized them into six groups based on their smoking history and habit change.
A Phase III study found that perioperative nivolumab plus chemotherapy significantly improved event-free survival in patients with resectable early-stage non-small cell lung cancer. The treatment also showed higher rates of pathological complete response and major pathological response compared to chemotherapy alone.
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
The prevalence of lung cancer mutations varies significantly across different ethnic groups in Latin America, highlighting the need for region-specific medical interventions. Enhancing molecular diagnostic and research efforts is crucial for effective management of cancer in this population.
A study published by University of Pittsburgh researchers found that ACA insurance expansions led to an increase in patients receiving care at accredited cancer hospitals in Pennsylvania. The study suggests that these expansions make a difference in improving access to high-quality cancer care, particularly for those living in areas wi...
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
A new study found that offering stop smoking support alongside lung cancer screening can significantly increase quit rates among high-risk individuals. Up to half of those who attend for lung cancer screening currently smoke, and dedicated funding is urged to provide this essential support.
Researchers at H. Lee Moffitt Cancer Center & Research Institute discovered a new therapeutic target for non-small cell lung cancer by targeting the Jagged2 protein. Disrupting this signaling pathway activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
Scientists at German Cancer Research Center have discovered a combination therapy that improves treatment response and delays resistance in lung cancer cells. The therapy, which combines ALK and SRC inhibitors, blocks key protein expression changes that lead to resistance.
Tetracycline antibiotics have been found to enhance the antitumor activity of T lymphocytes by targeting galactin-1, an immunosuppressive protein produced by cancer cells. This breakthrough discovery may lead to the development of new drugs that target different immune pathways and benefit patients with cancer.
A new lab assay developed by Fred Hutch Cancer Center researchers detects differences between types of lung cancer using patterns in cell-free tumor DNA. The blood-based test has the potential to classify clinical subtypes driven by transcriptional programs and expand treatment selection for patients with small-cell lung cancer.
The study assessed relationships between TCM syndromes and lung cancer TNM staging indicators, finding phlegm dampness syndrome dominant in stages I & II, Qi Yin deficiency syndrome in stages III & IV. The findings suggest bias in included literature, emphasizing the need for larger sample sizes and clinical experimental investigations.
A population-wide observational study found an association between tuberculosis (TB) and a higher incidence of various cancers. TB patients were more likely to be diagnosed with lung, blood, gynaecological, colorectal, thyroid, oesophagus, and stomach cancers compared to the general population.
A clinical trial from Keck Medicine of USC will investigate the feasibility of treating non-small cell lung cancer with immunotherapy provided at home. The study aims to enroll 37 patients and examine the safety, efficacy, and patient compliance with at-home treatment.